EPT-19PHASE I TRIAL OF PALBOCICLIB, A CDK4/6 INHIBITOR IN CHILDREN WITH RETINOBLASTOMA PROTEIN (RB1) + RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS (PBTC 042) | Zendy

AI Assistant Blog Pricing

EPT-19PHASE I TRIAL OF PALBOCICLIB, A CDK4/6 INHIBITOR IN CHILDREN WITH RETINOBLASTOMA PROTEIN (RB1) + RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS (PBTC 042)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.